A novel cancer immunotherapy shows early promise in preclinical studies

Scientists report that GARP, a TGF-beta cell surface receptor, could be a novel diagnostic marker for breast, colon, and lung cancer. An antibody-based therapy targeting GARP prevented metastasis to the lung in a mouse model of breast cancer. Targeting GARP with an antibody could represent a novel addition to established immunotherapies that ‚wake up‘ the immune system so that it can fight cancer. (Mehr in: Cancer News — ScienceDaily)